Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects

Indu Pal Kaur1, Parneet Kaur Deol, Kanthi Kiran Kondepudi

  • 1University Institute of Pharmaceutical Sciences, UGC Centre for Advance Study, Panjab University, Chandigarh-160014, INDIA. indupalkaur@yahoo.com.

Abstract

Insights

Ginger compounds like 6-gingerol show anticancer potential by inducing apoptosis and inhibiting metastasis. Overcoming poor bioavailability through formulation can unlock ginger

Area of Science:

  • Phytochemistry
  • Pharmacology
  • Oncology

Background:

  • Cancers are complex diseases requiring multitarget therapeutic strategies.
  • Current single-target treatments often fail, necessitating novel approaches.
  • Herbal medicines offer potential for multitargeting due to their complex chemical profiles.

Purpose of the Study:

  • To review the anticancer mechanisms of ginger.
  • To identify challenges limiting ginger's therapeutic use.
  • To explore strategies for enhancing ginger's biopharmaceutical properties.

Main Methods:

  • Review of in vitro and in vivo studies on ginger's anticancer effects.
  • Analysis of the chemical constituents of ginger, focusing on phenolic compounds.
  • Evaluation of biopharmaceutical limitations and formulation strategies.

Main Results:

  • Ginger possesses antioxidant, anti-inflammatory, and anticancer properties.
  • Key compounds like 6-gingerol and 6-shogaol induce apoptosis and autophagy, and inhibit metastasis.
  • Poor bioavailability of ginger extracts hinders therapeutic efficacy.

Conclusions:

  • Ginger's active compounds demonstrate significant anticancer potential.
  • Pharmaceutical formulation is crucial to overcome bioavailability issues.
  • Integrating traditional knowledge with scientific findings can yield effective, safe, and affordable cancer therapies.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K